Nu Skin Enterprises Financial Statements (NUS)
|
|
Report date
|
|
|
11.02.2021 |
16.02.2022 |
31.12.2022 |
16.02.2023 |
15.02.2024 |
|
08.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 582 |
2 696 |
2 226 |
2 226 |
1 969 |
|
1 775 |
Operating Income, bln rub |
|
|
257.6 |
234.0 |
159.3 |
110.8 |
48.3 |
|
84.0 |
EBITDA, bln rub |
? |
|
331.6 |
368.5 |
89.0 |
231.8 |
137.7 |
|
-9.22 |
Net profit, bln rub |
? |
|
191.4 |
147.3 |
104.8 |
104.8 |
8.60 |
|
-103.2 |
|
OCF, bln rub |
? |
|
379.1 |
141.6 |
|
108.1 |
118.6 |
|
140.1 |
CAPEX, bln rub |
? |
|
63.8 |
68.6 |
|
59.1 |
58.5 |
|
49.4 |
FCF, bln rub |
? |
|
315.3 |
73.0 |
|
49.0 |
60.1 |
|
90.7 |
Dividend payout, bln rub
|
|
|
78.4 |
76.3 |
|
77.0 |
77.6 |
|
28.2 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
41.0% |
51.8% |
0.00% |
73.5% |
903.1% |
|
-27.3% |
|
OPEX, bln rub |
|
|
1 666 |
1 735 |
1 435 |
1 435 |
1 289 |
|
1 171 |
Cost of production, bln rub |
|
|
658.0 |
675.2 |
630.9 |
630.9 |
611.9 |
|
520.0 |
R&D, bln rub |
|
|
23.3 |
27.2 |
0.000 |
23.3 |
22.6 |
|
22.6 |
Interest expenses, bln rub |
|
|
13.1 |
11.0 |
0.000 |
21.9 |
0.000 |
|
20.5 |
|
Assets, bln rub |
|
|
1 957 |
1 906 |
1 821 |
1 821 |
1 806 |
|
1 583 |
Net Assets, bln rub |
? |
|
894.3 |
912.8 |
897.3 |
897.3 |
822.0 |
|
706.9 |
Debt, bln rub |
|
|
500.4 |
465.0 |
479.0 |
479.0 |
607.3 |
|
501.8 |
Cash, bln rub |
|
|
423.9 |
354.8 |
278.5 |
278.5 |
267.8 |
|
227.8 |
Net debt, bln rub |
|
|
76.5 |
110.2 |
200.5 |
200.5 |
339.5 |
|
274.1 |
|
Ordinary share price, rub |
|
|
54.6 |
50.8 |
42.2 |
42.2 |
19.4 |
|
16.9 |
Number of ordinary shares, mln |
|
|
52.3 |
50.2 |
50.0 |
50.0 |
49.7 |
|
49.7 |
|
Market cap, bln rub |
|
|
2 857 |
2 547 |
2 108 |
2 108 |
965 |
|
838 |
EV, bln rub |
? |
|
2 933 |
2 658 |
2 309 |
2 309 |
1 305 |
|
1 112 |
Book value, bln rub |
|
|
602 |
629 |
624 |
624 |
486 |
|
522 |
|
EPS, rub |
? |
|
3.66 |
2.93 |
2.10 |
2.10 |
0.17 |
|
-2.08 |
FCF/share, rub |
|
|
6.03 |
1.45 |
0.00 |
0.98 |
1.21 |
|
1.83 |
BV/share, rub |
|
|
11.5 |
12.5 |
12.5 |
12.5 |
9.77 |
|
10.5 |
|
EBITDA margin, % |
? |
|
12.8% |
13.7% |
4.00% |
10.4% |
6.99% |
|
-0.52% |
Net margin, % |
? |
|
7.41% |
5.46% |
4.71% |
4.71% |
0.44% |
|
-5.81% |
FCF yield, % |
? |
|
11.0% |
2.86% |
0.00% |
2.32% |
6.23% |
|
10.8% |
ROE, % |
? |
|
21.4% |
16.1% |
11.7% |
11.7% |
1.05% |
|
-14.6% |
ROA, % |
? |
|
9.78% |
7.72% |
5.75% |
5.75% |
0.48% |
|
-6.52% |
|
P/E |
? |
|
14.9 |
17.3 |
20.1 |
20.1 |
112.3 |
|
-8.12 |
P/FCF |
|
|
9.06 |
34.9 |
|
43.0 |
16.0 |
|
9.24 |
P/S |
? |
|
1.11 |
0.94 |
0.95 |
0.95 |
0.49 |
|
0.47 |
P/BV |
? |
|
4.75 |
4.05 |
3.38 |
3.38 |
1.99 |
|
1.61 |
EV/EBITDA |
? |
|
8.85 |
7.21 |
25.9 |
9.96 |
9.48 |
|
-120.6 |
Debt/EBITDA |
|
|
0.23 |
0.30 |
2.25 |
0.86 |
2.47 |
|
-29.7 |
|
R&D/CAPEX, % |
|
|
36.5% |
39.6% |
|
39.5% |
38.6% |
|
45.8% |
|
CAPEX/Revenue, % |
|
|
2.47% |
2.55% |
0.00% |
2.65% |
2.97% |
|
2.78% |
|
Nu Skin Enterprises shareholders |